NEW ORLEANS, June 19, 2017 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of SciClone Pharmaceuticals, Inc. ("SciClone" or the "Company") (NASDAQ: SCLN) to a consortium of buyers. Under the terms of the proposed transaction, shareholders of SciClone will receive only $11.18 in cash for each share of SciClone that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (firstname.lastname@example.org) toll free at any time at 855-768-1857.
To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.
Kahn Swick & Foti, LLC
206 Covington St.
Madisonville, LA 70447
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/sciclone-investor-alert-by-the-former-attorney-general-of-louisiana-kahn-swick--foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-sciclone-pharmaceuticals-inc-300476007.html
SOURCE Kahn Swick & Foti, LLC